Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil
- PMID: 21340216
- PMCID: PMC3020338
- DOI: 10.1590/s1807-59322010001200010
Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil
Abstract
Objectives: We performed a national survey to update hepatocellular carcinoma (HCC) epidemiology in Brazil and determined the clinical and epidemiological profiles of patients with HCC in different Brazilian regions.
Methods: Data from 29 centers included 1,405 patients diagnosed with HCC from 2004 to 2009.
Results: The median age was 59 (1-92 years old; 78% male). At diagnosis, females were older than males (median age: 62 vs. 59 years old respectively; p<0.0001). Ninety-eight percent of the patients had cirrhosis (1279/1308). Hepatitis C virus was the main etiology (54%), followed by hepatitis B virus (16%) and alcohol (14%). In Southeastern and Southern Brazil, hepatitis C virus accounted for over 55% of cases. In the Northeast and North, hepatitis C virus accounted for less than 50%, and hepatitis B virus accounted for 22-25% of cases; hepatitis B was more prevalent in the Northern than in the Southern regions. Some 43%, 35%, and 22% of patients were in early, intermediate, and advanced stages respectively. Initial therapies for HCC included chemoembolization or embolization (36%), percutaneous ablation (13%), liver resection (7%), and sorafenib (1%). Liver transplantation was performed in 242 patients (19%), but it was the initial therapy for only 56 patients (4%).
Conclusion: The epidemiology, classification, and therapy selection for HCC varied among Brazilian regions. Hepatitis C infection was the most common etiology of liver cirrhosis; chemoembolization was the most common therapy employed. Liver cirrhosis was the main risk factor for HCC development in Brazil.
Figures




Similar articles
-
Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil.Antivir Ther. 2013;18(3 Pt B):445-9. doi: 10.3851/IMP2602. Epub 2013 Jun 21. Antivir Ther. 2013. PMID: 23793796 Review.
-
Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data.J Gastrointest Cancer. 2021 Sep;52(3):952-958. doi: 10.1007/s12029-020-00508-7. J Gastrointest Cancer. 2021. PMID: 32918274 Free PMC article.
-
Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.Ann Hepatol. 2017 March-April;16(2):255-262. doi: 10.5604/16652681.1231584. Ann Hepatol. 2017. PMID: 28233747
-
Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.Dig Dis Sci. 2020 Jul;65(7):2120-2129. doi: 10.1007/s10620-019-05938-3. Epub 2019 Nov 13. Dig Dis Sci. 2020. PMID: 31722058
-
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014. Gastroenterology. 2004. PMID: 15508101 Review.
Cited by
-
INDICATION FOR LIVER TRANSPLANTATION DUE TO HEPATOCELLULAR CARCINOMA: ANALYSIS OF 1,706 PROCEDURES OVER THE PAST DECADE IN THE STATE OF PARANÁ.Arq Bras Cir Dig. 2022 Dec 19;35:e1701. doi: 10.1590/0102-672020220002e1701. eCollection 2022. Arq Bras Cir Dig. 2022. PMID: 36542003 Free PMC article.
-
HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND OPERATIVE MANAGEMENT.Arq Bras Cir Dig. 2017 Oct-Dec;30(4):272-278. doi: 10.1590/0102-6720201700040011. Arq Bras Cir Dig. 2017. PMID: 29340553 Free PMC article. Review.
-
Pediatrics in Clinics: highlights.Clinics (Sao Paulo). 2012 Aug;67(8):859-64. doi: 10.6061/clinics/2012(08)01. Clinics (Sao Paulo). 2012. PMID: 22948450 Free PMC article. No abstract available.
-
Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.World J Gastroenterol. 2016 Jul 21;22(27):6246-56. doi: 10.3748/wjg.v22.i27.6246. World J Gastroenterol. 2016. PMID: 27468214 Free PMC article.
-
Clinical impact of the Model for End Liver Disease (MELD) score on the presence of microvascular invasion and on the postoperative outcome in patients undergoing liver transplantation.Rev Col Bras Cir. 2021 Dec 20;48:e20212997. doi: 10.1590/0100-6991e-20212997. eCollection 2021. Rev Col Bras Cir. 2021. PMID: 34932735 Free PMC article.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. 10.3322/canjclin.55.2.74 - DOI - PubMed
-
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50. 10.1053/j.gastro.2004.09.014 - DOI - PubMed
-
- Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211. 10.1016/j.cld.2004.12.009 - DOI - PubMed
-
- El‐Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–34. 10.1053/j.gastro.2004.09.013 - DOI - PubMed
-
- Gonçalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianópolis, SC, 1995) Rev Inst Med Trop Sao Paulo. 1997;39:165–70. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical